Ionis Pharmaceuticals (IONS) Projected to Post Earnings on Wednesday

Ionis Pharmaceuticals (NASDAQ:IONS) is expected to be releasing its Q1 2026 results before the market opens on Wednesday, April 29th. Analysts expect Ionis Pharmaceuticals to post earnings of ($0.8471) per share and revenue of $197.4520 million for the quarter. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, April 29, 2026 at 8:30 AM ET.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.18). The firm had revenue of $203.33 million for the quarter, compared to analysts’ expectations of $156.07 million. Ionis Pharmaceuticals had a negative return on equity of 68.82% and a negative net margin of 40.36%.The firm’s revenue was down 10.6% on a year-over-year basis. During the same period last year, the company earned ($0.66) earnings per share. On average, analysts expect Ionis Pharmaceuticals to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Ionis Pharmaceuticals Stock Performance

IONS stock opened at $73.27 on Monday. The firm has a fifty day moving average price of $75.97 and a 200 day moving average price of $77.27. Ionis Pharmaceuticals has a fifty-two week low of $28.87 and a fifty-two week high of $86.74. The company has a debt-to-equity ratio of 2.76, a quick ratio of 3.81 and a current ratio of 3.83. The firm has a market cap of $12.10 billion, a PE ratio of -30.03 and a beta of 0.40.

Analyst Upgrades and Downgrades

IONS has been the topic of a number of recent research reports. Barclays upped their price target on shares of Ionis Pharmaceuticals from $95.00 to $106.00 and gave the company an “overweight” rating in a research note on Thursday, March 26th. Stifel Nicolaus boosted their target price on shares of Ionis Pharmaceuticals from $73.00 to $77.00 and gave the stock a “hold” rating in a report on Thursday, February 26th. Bank of America upped their target price on shares of Ionis Pharmaceuticals from $100.00 to $111.00 and gave the company a “buy” rating in a research report on Thursday, April 9th. Leerink Partners increased their price target on shares of Ionis Pharmaceuticals from $102.00 to $104.00 and gave the company an “outperform” rating in a report on Tuesday, March 3rd. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of Ionis Pharmaceuticals in a research report on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $97.35.

Insider Buying and Selling

In other Ionis Pharmaceuticals news, Director Allene M. Diaz sold 54,878 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $79.35, for a total value of $4,354,569.30. Following the completion of the transaction, the director directly owned 3,811 shares in the company, valued at approximately $302,402.85. The trade was a 93.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Kyle Jenne sold 37,277 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $75.85, for a total transaction of $2,827,460.45. Following the transaction, the executive vice president owned 11,714 shares of the company’s stock, valued at approximately $888,506.90. This trade represents a 76.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 864,155 shares of company stock valued at $67,020,422 over the last three months. Corporate insiders own 2.71% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD raised its stake in Ionis Pharmaceuticals by 9.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,987,840 shares of the company’s stock valued at $236,370,000 after buying an additional 258,155 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Ionis Pharmaceuticals by 1.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,541,841 shares of the company’s stock worth $121,975,000 after acquiring an additional 21,890 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Ionis Pharmaceuticals by 20.3% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,388,567 shares of the company’s stock worth $109,850,000 after acquiring an additional 234,401 shares during the last quarter. Artisan Partners Limited Partnership increased its holdings in shares of Ionis Pharmaceuticals by 32.7% during the fourth quarter. Artisan Partners Limited Partnership now owns 1,181,416 shares of the company’s stock valued at $93,462,000 after acquiring an additional 291,344 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Ionis Pharmaceuticals by 45.9% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,154,166 shares of the company’s stock valued at $75,506,000 after purchasing an additional 363,094 shares during the last quarter. 93.86% of the stock is currently owned by hedge funds and other institutional investors.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.